Abstract
The CD4 molecule is an essential receptor for human immunodeficiency virus type 1 (HIV-1) through high-affinity interactions with the viral external envelope glycoprotein gp120. Previously, neutralizing monoclonal antibodies (MAbs) specific to the third hypervariable domain of gp120 (the V3 loop) have been thought to block HIV infection without affecting the binding of HIV particles to CD4-expressing human cells. However, here we demonstrate that this conclusion was not correct and was due to the use of soluble gp120 instead of HIV particles. Indeed, neutralizing anti-V3 loop MAbs inhibited completely the binding and entry of HIV particles into CD4+ human cells. In contrast, the binding of virus was only partially inhibited by neutralizing anti-CD4 MAbs against the gp120 binding site in CD4, which, like the anti-V3 loop MAbs, completely inhibited HIV entry and infection. Nonneutralizing control MAbs against either the V3 loop or the N or C terminus of gp120 had no significant effect on HIV binding and entry. HIV-1 particles were also found to bind human and murine cells expressing or not expressing the human CD4 molecule. Interestingly, the binding of HIV to CD4+ murine cells was inhibited by both anti-V3 and anti-CD4 MAbs, whereas the binding to human and murine CD4- cells was affected only by anti-V3 loop MAbs. The effect of anti-V3 loop neutralizing MAbs on the HIV binding to cells appears not to be the direct consequence of gp120 shedding from HIV particles or of a decreased affinity of CD4 or gp120 for binding to its surface counterpart. Taken together, our results suggest the existence of CD4-dependent and -independent binding events involved in the attachment of HIV particles to cells; in both of these events, the V3 loop plays a critical role. As murine cells lack the specific cofactor CXCR4 for HIV-1 entry, other cell surface molecules besides CD4 might be implicated in stable binding of HIV particles to cells.
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barbas C. F., 3rd, Björling E., Chiodi F., Dunlop N., Cababa D., Jones T. M., Zebedee S. L., Persson M. A., Nara P. L., Norrby E. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339–9343. doi: 10.1073/pnas.89.19.9339. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blank U., Boitel B., Mège D., Ermonval M., Acuto O. Analysis of tetanus toxin peptide/DR recognition by human T cell receptors reconstituted into a murine T cell hybridoma. Eur J Immunol. 1993 Dec;23(12):3057–3065. doi: 10.1002/eji.1830231203. [DOI] [PubMed] [Google Scholar]
- Bour S., Geleziunas R., Wainberg M. A. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev. 1995 Mar;59(1):63–93. doi: 10.1128/mr.59.1.63-93.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Burton D. R., Barbas C. F., 3rd, Persson M. A., Koenig S., Chanock R. M., Lerner R. A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134–10137. doi: 10.1073/pnas.88.22.10134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Callebaut C., Jacotot E., Guichard G., Krust B., Rey-Cuille M., Cointe D., Benkirane N., Blanco J., Muller S., Briand J. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Virology. 1996 Apr 1;218(1):181–192. doi: 10.1006/viro.1996.0178. [DOI] [PubMed] [Google Scholar]
- Callebaut C., Jacotot E., Krust B., Guichard G., Blanco J., Valenzuela A., Svab J., Muller S., Briand J. P., Hovanessian A. G. Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein. J Biol Chem. 1997 Mar 14;272(11):7159–7166. doi: 10.1074/jbc.272.11.7159. [DOI] [PubMed] [Google Scholar]
- Callebaut C., Krust B., Jacotot E., Hovanessian A. G. T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science. 1993 Dec 24;262(5142):2045–2050. doi: 10.1126/science.7903479. [DOI] [PubMed] [Google Scholar]
- Chin L. T., Dueñas M., Levi M., Hinkula J., Wahren B., Borrebaeck C. A. Molecular characterization of a human anti-HIV 1 monoclonal antibody revealed a CD26-related motif in CDR2. Immunol Lett. 1995 Jan;44(1):25–30. doi: 10.1016/0165-2478(94)00192-t. [DOI] [PubMed] [Google Scholar]
- Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996 Jun 28;85(7):1135–1148. doi: 10.1016/s0092-8674(00)81313-6. [DOI] [PubMed] [Google Scholar]
- Cordell J., Moore J. P., Dean C. J., Klasse P. J., Weiss R. A., McKeating J. A. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology. 1991 Nov;185(1):72–79. doi: 10.1016/0042-6822(91)90755-z. [DOI] [PubMed] [Google Scholar]
- D'Souza M. P., Harden V. A. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat Med. 1996 Dec;2(12):1293–1300. doi: 10.1038/nm1296-1293. [DOI] [PubMed] [Google Scholar]
- Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984 Dec 20;312(5996):763–767. doi: 10.1038/312763a0. [DOI] [PubMed] [Google Scholar]
- Demaria S., Bushkin Y. Soluble CD4 induces the binding of human immunodeficiency virus type 1 to cells via the V3 loop of glycoprotein 120 and specific sites in glycoprotein 41. AIDS Res Hum Retroviruses. 1996 Mar 1;12(4):281–290. doi: 10.1089/aid.1996.12.281. [DOI] [PubMed] [Google Scholar]
- Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E., Hill C. M. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20;381(6584):661–666. doi: 10.1038/381661a0. [DOI] [PubMed] [Google Scholar]
- Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C., Parmentier M., Collman R. G., Doms R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996 Jun 28;85(7):1149–1158. doi: 10.1016/s0092-8674(00)81314-8. [DOI] [PubMed] [Google Scholar]
- Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996 Jun 20;381(6584):667–673. doi: 10.1038/381667a0. [DOI] [PubMed] [Google Scholar]
- Feng Y., Broder C. C., Kennedy P. E., Berger E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996 May 10;272(5263):872–877. doi: 10.1126/science.272.5263.872. [DOI] [PubMed] [Google Scholar]
- Harouse J. M., Bhat S., Spitalnik S. L., Laughlin M., Stefano K., Silberberg D. H., Gonzalez-Scarano F. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science. 1991 Jul 19;253(5017):320–323. doi: 10.1126/science.1857969. [DOI] [PubMed] [Google Scholar]
- Harouse J. M., Collman R. G., González-Scarano F. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line. J Virol. 1995 Dec;69(12):7383–7390. doi: 10.1128/jvi.69.12.7383-7390.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harrop H. A., Coombe D. R., Rider C. C. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS. 1994 Feb;8(2):183–192. doi: 10.1097/00002030-199402000-00005. [DOI] [PubMed] [Google Scholar]
- Hildreth J. E., Orentas R. J. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science. 1989 Jun 2;244(4908):1075–1078. doi: 10.1126/science.2543075. [DOI] [PubMed] [Google Scholar]
- Jacotot E., Callebaut C., Blanco J., Rivière Y., Krust B., Hovanessian A. G. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells. Virology. 1996 Sep 15;223(2):318–330. doi: 10.1006/viro.1996.0483. [DOI] [PubMed] [Google Scholar]
- Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J. C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 1984 Dec 20;312(5996):767–768. doi: 10.1038/312767a0. [DOI] [PubMed] [Google Scholar]
- Krust B., Callebaut C., Hovanessian A. G. Inhibition of entry of HIV into cells by poly(A).poly(U). AIDS Res Hum Retroviruses. 1993 Nov;9(11):1087–1090. doi: 10.1089/aid.1993.9.1087. [DOI] [PubMed] [Google Scholar]
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- Laman J. D., Schellekens M. M., Abacioglu Y. H., Lewis G. K., Tersmette M., Fouchier R. A., Langedijk J. P., Claassen E., Boersma W. J. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J Virol. 1992 Mar;66(3):1823–1831. doi: 10.1128/jvi.66.3.1823-1831.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lapham C. K., Ouyang J., Chandrasekhar B., Nguyen N. Y., Dimitrov D. S., Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science. 1996 Oct 25;274(5287):602–605. doi: 10.1126/science.274.5287.602. [DOI] [PubMed] [Google Scholar]
- Laurent-Crawford A. G., Hovanessian A. G. The cytopathic effect of human immunodeficiency virus is independent of high levels of unintegrated viral DNA accumulated in response to superinfection of cells. J Gen Virol. 1993 Dec;74(Pt 12):2619–2628. doi: 10.1099/0022-1317-74-12-2619. [DOI] [PubMed] [Google Scholar]
- Laurent A. G., Krust B., Galabru J., Svab J., Hovanessian A. G. Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4341–4345. doi: 10.1073/pnas.82.13.4341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Linsley P. S., Ledbetter J. A., Kinney-Thomas E., Hu S. L. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol. 1988 Oct;62(10):3695–3702. doi: 10.1128/jvi.62.10.3695-3702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McDougal J. S., Kennedy M. S., Orloff S. L., Nicholson J. K., Spira T. J. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol. 1996 Aug;70(8):5236–5245. doi: 10.1128/jvi.70.8.5236-5245.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McInerney T. L., McLain L., Armstrong S. J., Dimmock N. J. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology. 1997 Jul 7;233(2):313–326. doi: 10.1006/viro.1997.8547. [DOI] [PubMed] [Google Scholar]
- McKeating J. A., Cordell J., Dean C. J., Balfe P. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology. 1992 Dec;191(2):732–742. doi: 10.1016/0042-6822(92)90249-o. [DOI] [PubMed] [Google Scholar]
- McKeating J. A., Thali M., Furman C., Karwowska S., Gorny M. K., Cordell J., Zolla-Pazner S., Sodroski J., Weiss R. A. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology. 1992 Sep;190(1):134–142. doi: 10.1016/0042-6822(92)91199-5. [DOI] [PubMed] [Google Scholar]
- Moore J. P., Ho D. D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS. 1995;9 (Suppl A):S117–S136. [PubMed] [Google Scholar]
- Moore J. P., Nara P. L. The role of the V3 loop of gp120 in HIV infection. AIDS. 1991;5 (Suppl 2):S21–S33. doi: 10.1097/00002030-199101001-00004. [DOI] [PubMed] [Google Scholar]
- Niwa Y., Yano M., Futaki S., Okumura Y., Kido H. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. Eur J Biochem. 1996 Apr 1;237(1):64–70. doi: 10.1111/j.1432-1033.1996.0064n.x. [DOI] [PubMed] [Google Scholar]
- Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J. L., Arenzana-Seisdedos F., Schwartz O., Heard J. M., Clark-Lewis I., Legler D. F. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996 Aug 29;382(6594):833–835. doi: 10.1038/382833a0. [DOI] [PubMed] [Google Scholar]
- Olshevsky U., Helseth E., Furman C., Li J., Haseltine W., Sodroski J. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol. 1990 Dec;64(12):5701–5707. doi: 10.1128/jvi.64.12.5701-5707.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oravecz T., Pall M., Norcross M. A. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol. 1996 Aug 15;157(4):1329–1332. [PubMed] [Google Scholar]
- Oravecz T., Roderiquez G., Koffi J., Wang J., Ditto M., Bou-Habib D. C., Lusso P., Norcross M. A. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. Nat Med. 1995 Sep;1(9):919–926. doi: 10.1038/nm0995-919. [DOI] [PubMed] [Google Scholar]
- Patel M., Yanagishita M., Roderiquez G., Bou-Habib D. C., Oravecz T., Hascall V. C., Norcross M. A. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses. 1993 Feb;9(2):167–174. doi: 10.1089/aid.1993.9.167. [DOI] [PubMed] [Google Scholar]
- Pinter A., Honnen W. J., Tilley S. A. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J Virol. 1993 Sep;67(9):5692–5697. doi: 10.1128/jvi.67.9.5692-5697.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Poignard P., Fouts T., Naniche D., Moore J. P., Sattentau Q. J. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med. 1996 Feb 1;183(2):473–484. doi: 10.1084/jem.183.2.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roderiquez G., Oravecz T., Yanagishita M., Bou-Habib D. C., Mostowski H., Norcross M. A. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol. 1995 Apr;69(4):2233–2239. doi: 10.1128/jvi.69.4.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sattentau Q. J. Neutralization of HIV-1 by antibody. Curr Opin Immunol. 1996 Aug;8(4):540–545. doi: 10.1016/s0952-7915(96)80044-6. [DOI] [PubMed] [Google Scholar]
- Sommerfelt M. A., Asjö B. Intercellular adhesion molecule 3, a candidate human immunodeficiency virus type 1 co-receptor on lymphoid and monocytoid cells. J Gen Virol. 1995 Jun;76(Pt 6):1345–1352. doi: 10.1099/0022-1317-76-6-1345. [DOI] [PubMed] [Google Scholar]
- Starcich B. R., Hahn B. H., Shaw G. M., McNeely P. D., Modrow S., Wolf H., Parks E. S., Parks W. P., Josephs S. F., Gallo R. C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. doi: 10.1016/0092-8674(86)90778-6. [DOI] [PubMed] [Google Scholar]
- Thomas E. K., Weber J. N., McClure J., Clapham P. R., Singhal M. C., Shriver M. K., Weiss R. A. Neutralizing monoclonal antibodies to the AIDS virus. AIDS. 1988 Feb;2(1):25–29. doi: 10.1097/00002030-198802000-00004. [DOI] [PubMed] [Google Scholar]
- Trkola A., Dragic T., Arthos J., Binley J. M., Olson W. C., Allaway G. P., Cheng-Mayer C., Robinson J., Maddon P. J., Moore J. P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996 Nov 14;384(6605):184–187. doi: 10.1038/384184a0. [DOI] [PubMed] [Google Scholar]
- Valenzuela A., Blanco J., Callebaut C., Jacotot E., Lluis C., Hovanessian A. G., Franco R. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol. 1997 Apr 15;158(8):3721–3729. [PubMed] [Google Scholar]
- Willey R. L., Rutledge R. A., Dias S., Folks T., Theodore T., Buckler C. E., Martin M. A. Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5038–5042. doi: 10.1073/pnas.83.14.5038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A. A., Desjardin E., Newman W. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996 Nov 14;384(6605):179–183. doi: 10.1038/384179a0. [DOI] [PubMed] [Google Scholar]
- Yahi N., Sabatier J. M., Baghdiguian S., Gonzalez-Scarano F., Fantini J. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line. J Virol. 1995 Jan;69(1):320–325. doi: 10.1128/jvi.69.1.320-325.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]